PEBP1 and acute myeloid leukemia: Another possibility for the potential use of RKIP in optimizing therapeutic approaches stems from the observation that RKIP loss co-occurs with RAS-signaling mutations in MNs, including AML, and that this co-occurrence has been shown to hyperactivate the RAS-MAPK pathway in in vitro and in vivo models [21,56,62].